Dr John Bushweller speaks with ecancertv at AACR 2016 about his efforts to target transcription factors as cancer therapy.

Transcription factors have historically been too transient to effectively control gene expression in tumour cells, but Dr Bushweller describes a novel technique to inhibit transcription factor fusion that has resulted in restoring normal gene expression to cells.

Gene alteration in situ is itself a hallmark of tumourigenesis, and Dr Bushweller reports that combination with activated kinase therapy may be able to limit cancer mutagenesis.

свернуть